Pfizer-Allergan and the New U.S. Tax Inversion Rule

A potential $160 billion merger between Pfizer and Allergan may be put in jeopardy by new steps taken by the U.S. government to limit tax-cutting in corporate inversions. Bloomberg's Intelligence's Sam Fazeli explains on "Bloomberg ‹GO›." (Source: Bloomberg)

China Government Taking on More Risk, Says Darby
42:19 - Sean Darby, and Julia Coronado, president and founder at Macropolicy Perspectives LLC, examine China's economy as S&P downgrades the nation's sovereign credit rating. They speak on "Bloomberg Daybreak: Americas." (Source: Bloomberg)
  • Macron Has Support of French Business, Says Attias
  • U.S. to Be Alone on Iran Sanctions, Says Ischinger
  • Germany Losing a Symbol of the West, Says Ischinger